Covaxin well-tolerated: Phase 1 peer-review
Bharat Biotech Covaxin was well tolerated with no vaccine-related serious adverse events in a small group of volunteers, according to a peer review of the company’s phase 1 clinical trials published in the journal Lancet Infectious Diseases on Friday.
“…BBV152(Covaxin) led to tolerable safety outcomes and enhanced immune responses… BBV152 induced binding and neutralising antibody responses that were similar to those induced by other SARS-CoV-2 inactivated vaccine candidates,” the study said, in line with the data preprint data released by the company.
Phase 1 clinical trials are mostly used to test safety of a vaccine and the effects of various doses and combinations. The company found that there was no significant difference in the highest dose it tested as compared to the lowest, making the case for the higher dose to be used.
The overall incidence of solicited local and systemic adverse events in this study was 14–21%. The most common adverse event was pain at the injection site, followed by headache, fatigue, and fever.
Between July 13 and 30, 2020, 827 participants were screened, of whom 375 participants were randomized equally to receive three vaccine formulations in groups of 100 each (doses were as 3ug with Algel-IMDG, 6ug with Algel-IMDG or 6ug with Algel) while the control group had 75 participants. Algel and Algel-IMDG refer to different kinds of adjuvants -- additives that are designed to enhance immune response.
The whole-virion inactivated virus vaccine has been made in collaboration with the Indian Council of Medical Research (ICMR). The vaccine is still in phase 3 trials -- where it is being tested in over 25,000 people for safety and efficacy -- but has been approved for emergency use. The other vaccine, Covishield, has safety and efficacy data from phase III trials.
Hundreds of thousands of people have already received it, and experts believe the controversy around Covaxin still not clearing adequate levels in trials may be contributing to hesitancy. On Thursday, centres administering Covishield showed over 75% turnout while in those with Covaxin, less than 30% turned up.
“13,000 volunteers have been successfully administered the 2nd dose in the phase 3 clinical trials of Covaxin. My heartfelt thanks to all of them for their pro-vaccine public health volunteerism,” said Suchitra Ella, joint managing director, Bharat Biotech International Ltd.
Enter your email to get our daily newsletter in your inbox
- Addressing the concluding session of Bharatiya Janata Party (BJP) state president K Surendran’s “Vijay Yatra” in the state capital, Shah posed five questions to the CM.
- Addressing a state conference for its cadres on the outskirts of Trichy, Stalin said a DMK government will give ₹1,000 every month to housewives and create a million jobs every month.
- The meeting came a week after Tewari and other letter writers, the group has been tagged the G23, addressed a meeting in Jammu in honour of retired MP Ghulam Nabi Azad.
- In Tamil Nadu, the Congress is in alliance with the Dravida Munnetra Kazhagham (DMK).
- The observations from the Union health ministry come a day after the country reported the largest single-day increase in new Covid-19 infections in two months.
- Smriti Irani says, "I’m the only female politician who’s also recognised by her former vocation. I recognise the bias in that."
- An official said that both Houses could meet at 11 am from the second week following the vaccination of eligible MPs.
- A suicide note found at the spot said they took the decision because of acute financial distress, an official said.
- The changes have been opposed by some states who see it as another attempt by the Centre to take over mining auctions and impose central rules on a state domain.
- A re-invigorated biodiversity management policy is India’s survival strategy. At this point in our development trajectory, we don’t pay any heed to either biodiversity or landscape conservation.
- According to Forest Survey of India’s forest fire alert system, there were 2,317 fire points last year between February 26 and March 7, but the figure rose to 53,211 this time after data from the Suomi National Polar-orbiting Partnership (SNPP) was taken into account.